This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TAK vs. DSNKY: Which Stock Is the Better Value Option?
by Zacks Equity Research
TAK vs. DSNKY: Which Stock Is the Better Value Option?
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ADMA Loses 8.9% in a Month: How Should You Play the Stock?
by Ekta Bagri
ADMA Biologics' shares lose 8.9% in a month after putting up a phenomenal performance in the past 12 months. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.
ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?
by Zacks Equity Research
ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
by Ekta Bagri
ADMA Biologics has performed phenomenally in 2024. Given its strong trajectory, we recommend investors use any dip in the stock price as a buying opportunity.
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?
by Zacks Equity Research
ADMA is having a stupendous run in 2024 so far on strong performance of Asceniv and high growth prospects.
ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock?
by Ekta Bagri
ADMA stock rallies 262.1% in the year-to-date period on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
TAK or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TAK vs. CTLT: Which Stock Is the Better Value Option?
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
by Zacks Equity Research
TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.
How Many Stocks Should You Own?
by Tracey Ryniec
Even though there are dozens of great value stocks, that doesn't mean you should own them all.
Here is the Year-End FOMC Outlook
by John Blank
After the FOMC cut 50 bps, here is what to expect.
The Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America
by Zacks Equity Research
Takeda Pharma, Naspers and Packaging Corp. of America are part of the Zacks top Analyst Blog.
The Future Path of U.S. Inflation? Global Week Ahead
by John Blank
U.S. PCE inflation data for August and global business PMI activity surveys for September chart the pressure ahead.
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?
by Ekta Bagri
ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
TAK vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
TAK vs. STVN: Which Stock Is the Better Value Option?
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?
by Ekta Bagri
The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
by Zacks Equity Research
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
by Zacks Equity Research
Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
by Zacks Equity Research
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
by Zacks Equity Research
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
by Zacks Equity Research
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
TAK or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TAK vs. CTLT: Which Stock Is the Better Value Option?
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.